[China Pharmaceutical Network Technology News] Vitamin C + traditional medicine can improve the anti-cancer effect? Recently, Van Andel Institute scientists found that when the drug decitabine is used to treat myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), the extra vitamin C supplement can effectively enhance the drug inhibition of cancer. Cell expansion, the ability to trigger cancer in cancer cells. This latest achievement reflects the trend of combination therapy, especially with regard to epigenetic treatment.
Vitamin C + traditional medicine: improve anti-cancer effect
The simple, low-cost adjustment of vitamin C supplementation is expected to improve the effectiveness of MDS and AML standard epigenetic treatment. Many cancer patients lack vitamin C in their bodies, and the research team is trying to make up for this deficiency and unexpectedly found it to have a positive impact on treatment.
To validate laboratory results, the team selected a similar drug, azacitidine, in combination with vitamin C as a combination therapy and put it into clinical trials.
The author of the article, Dr. Peter Jones, chief scientific officer of the Van Andel Institute, said that if the pilot trial is successful, they will continue to conduct a larger clinical trial to verify the ability of vitamin C to improve the current therapeutic effects of AML and MDS. The clinical trial of "azacitidine + vitamin / placebo" is a necessary step to answer whether vitamin C can enhance the efficacy of anticancer drugs.
Dr. Jones emphasized that only a subset of patients with AML or MDS are eligible for this clinical trial because they have not found evidence that this method is applicable to other cancers.
Combination therapy is the trend
This latest achievement reflects the trend of combination therapy, especially with regard to epigenetic treatment.
When key gene expression or silent selection is wrong, it is easy to cause cell cancer. Epigenetics is a "switch" that regulates the expression of a gene. It usually corrects such errors in two ways: correcting the position of the gene switch; allowing the cell to appear in a state similar to being infected by a virus, thereby being recognized and eliminated by the immune system.
The clinical trial, led by Dr. Kirsten Grønbæk, MD, chief hematologist and professor at the University of Copenhagen, will recruit 20 patients and expects preliminary results in the first half of next year.
Dr. Grønbæk said: "The prospects for combination therapy are good, but a lot of research work is needed to ensure its safety and effectiveness. Once the verification is successful, it means that small changes can make great progress. Of course, as a doctor I strongly recommend that patients wait patiently for clinical results, whether they are taking medication or dietary supplements, they need to consult an attending physician."
Vitamin C + traditional medicine: improve anti-cancer effect
The simple, low-cost adjustment of vitamin C supplementation is expected to improve the effectiveness of MDS and AML standard epigenetic treatment. Many cancer patients lack vitamin C in their bodies, and the research team is trying to make up for this deficiency and unexpectedly found it to have a positive impact on treatment.
To validate laboratory results, the team selected a similar drug, azacitidine, in combination with vitamin C as a combination therapy and put it into clinical trials.
The author of the article, Dr. Peter Jones, chief scientific officer of the Van Andel Institute, said that if the pilot trial is successful, they will continue to conduct a larger clinical trial to verify the ability of vitamin C to improve the current therapeutic effects of AML and MDS. The clinical trial of "azacitidine + vitamin / placebo" is a necessary step to answer whether vitamin C can enhance the efficacy of anticancer drugs.
Dr. Jones emphasized that only a subset of patients with AML or MDS are eligible for this clinical trial because they have not found evidence that this method is applicable to other cancers.
Combination therapy is the trend
This latest achievement reflects the trend of combination therapy, especially with regard to epigenetic treatment.
When key gene expression or silent selection is wrong, it is easy to cause cell cancer. Epigenetics is a "switch" that regulates the expression of a gene. It usually corrects such errors in two ways: correcting the position of the gene switch; allowing the cell to appear in a state similar to being infected by a virus, thereby being recognized and eliminated by the immune system.
The clinical trial, led by Dr. Kirsten Grønbæk, MD, chief hematologist and professor at the University of Copenhagen, will recruit 20 patients and expects preliminary results in the first half of next year.
Dr. Grønbæk said: "The prospects for combination therapy are good, but a lot of research work is needed to ensure its safety and effectiveness. Once the verification is successful, it means that small changes can make great progress. Of course, as a doctor I strongly recommend that patients wait patiently for clinical results, whether they are taking medication or dietary supplements, they need to consult an attending physician."
GMP ATS Injection, Tetanus Antitoxin, Tetanus Toxoid ,Tetanus Antitoxin Injection, Antitetanus, Refined Tetanus Antitoxinsupplier in China
Tetanus Antitoxin,Tetanus Toxoid,Tetanus Antitoxin Injection,Antitetanus&Refined Tetanus Antitoxin
FOSHAN PHARMA CO., LTD. , https://www.fospharma.com